Conveners
Parallel Session 10: Advanced Materials 2 & Soft Matter 2 - Sponsored by Melbourne Centre for Nanofabrication (MCN)
- Stephen Holt (Australian Nuclear Science and Technology Organisation)
-
Dr Cara Doherty (CSIRO)23/11/2018, 11:00Advanced MaterialsOral
Biomolecules such as enzymes, DNA and other proteins are increasingly being used in various biotechnology and industrial applications. However, they rely on their structural complexity for activity and specificity [1] making them vulnerable to environmental factors such as temperature, pH, and solvents. Encapsulation of these molecules, especially enzymes, improves their stability and allows...
Go to contribution page -
Dr Hannah Wells (Massey University)23/11/2018, 11:30Advanced MaterialsOral
Collagen tissues such as skin and pericardium are remarkably strong and malleable. These physical charactersitics, along with the biocompatibility benefits of being a natural product, make collagen tissues an excellent source material for making surgical patches and implants. Our studies have involved investigating the natural collagen structure within acellular dermal matrix (ADM) materials...
Go to contribution page -
Susyn Kelly (Massey University)23/11/2018, 11:45Advanced MaterialsOral
Flexibility and strength are both desirable characteristics in skin derived collagen materials, like leather. Dehydration of skin during production of leather transforms tissue into a stiffer material. The hydration state is a key parameter in leather production controlling the material strength and flexibility. The structural basis for flexibility in leather was investigated and the moisture...
Go to contribution page -
Malinda Salim (Monash Institute of Pharmaceutical Sciences)23/11/2018, 12:00Advanced MaterialsOral
Strategies to administer drugs in a low cost and an effective manner are priorities to global health and many efforts have been made to re-formulate drugs that are highly lipophilic and have high variations in their oral bioavailability. One example of such drug is clofazimine, which has been recently identified as a potential new drug to treat cryptosporidiosis, the second leading cause of...
Go to contribution page -
Andrew Clulow (Monash University)23/11/2018, 12:15Advanced MaterialsOral
Andrew J. Clulow(1), Malinda Salim(1), Anna C. Pham(1), Gisela Ramirez(1), Adrian Hawley(2) and Ben J. Boyd(1,3)
*(1) Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC 3052, Australia
Go to contribution page
(2) Australian Synchrotron, ANSTO, 800 Blackburn Road, Clayton, VIC 3168, Australia
(3) Centre of Excellence for Convergent Bio-Nano...